ATV/r + TDF/FTC or DRV/r + TDF/FTC — Competitive Intelligence Brief

ATV/r + TDF/FTC or DRV/r + TDF/FTC (ATV/r + TDF/FTC or DRV/r + TDF/FTC) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors). Area: Infectious Disease / Virology.

phase 3 Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors) HIV protease; HIV reverse transcriptase Infectious Disease / Virology Small molecule

Target snapshot

ATV/r + TDF/FTC or DRV/r + TDF/FTC (ATV/r + TDF/FTC or DRV/r + TDF/FTC) — Juan A. Arnaiz. This is a combination antiretroviral regimen that uses protease inhibitors (boosted with ritonavir) plus nucleoside reverse transcriptase inhibitors to suppress HIV replication by blocking viral protease and reverse transcriptase enzymes.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ATV/r + TDF/FTC or DRV/r + TDF/FTC TARGET	ATV/r + TDF/FTC or DRV/r + TDF/FTC	Juan A. Arnaiz	phase 3	Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease; HIV reverse transcriptase
Reyataz + Epzicom	Reyataz + Epzicom	ViiV Healthcare	marketed	Antiretroviral combination (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease; HIV reverse transcriptase
LPV/r + TDF/FTC or TDF/3TC	LPV/r + TDF/FTC or TDF/3TC	The HIV Netherlands Australia Thailand Research Collaboration	marketed	Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease; HIV reverse transcriptase
Ritonavir boosted Atazanavir + Lamivudine	Ritonavir boosted Atazanavir + Lamivudine	Fundacion SEIMC-GESIDA	marketed	Antiretroviral combination (protease inhibitor + nucleoside reverse transcriptase inhibitor)	HIV protease; HIV reverse transcriptase
Atazanavir + 2 NRTIs	Atazanavir + 2 NRTIs	Bristol-Myers Squibb	marketed	Protease inhibitor (PI) + nucleoside reverse transcriptase inhibitors (NRTIs)	HIV protease; HIV reverse transcriptase
Lopinavir/ritonavir + nevirapine	Lopinavir/ritonavir + nevirapine	Amsterdam UMC, location VUmc	marketed	Antiretroviral combination therapy (protease inhibitor + non-nucleoside reverse transcriptase inhibitor)	HIV protease; HIV reverse transcriptase
Lopinavir/ritonavir + zidovudine + lamivudine	Lopinavir/ritonavir + zidovudine + lamivudine	Amsterdam UMC, location VUmc	marketed	Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors) class)

1. Bristol-Myers Squibb · 3 drugs in this class
2. Juan A. Arnaiz · 2 drugs in this class
3. National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class
4. The HIV Netherlands Australia Thailand Research Collaboration · 1 drug in this class
5. University of Cologne · 1 drug in this class
6. Amsterdam UMC, location VUmc · 1 drug in this class
7. ViiV Healthcare · 1 drug in this class
8. Drugs for Neglected Diseases · 1 drug in this class